MENU
CLOSE
At Conexeu, we are developing CXU™ as a next-generation collagen-based ECM platform for tissue regeneration, designed to move beyond static fillers and more closely reflect the biology of the body’s native extracellular matrix. By combining immediate structural support with the potential for tissue in-growth and longer-term integration, our goal is to create a more regenerative approach to soft-tissue restoration.
One platform, one formula, one device for broad potential use across a range of human and animal applications.
.png)
.avif)
30-year global healthcare leader developing and building category-defining brands. Current board member of Castle Biosciences (CSTL), a precision diagnostics company.
8-Figure Exit, Novaestiq Corp. Co-Founder & CEO, built the ‘next-generation’ aesthetics platform, raised $10M+ pre-Series A, and FDA approved in Sept ’25.
Member of Galderma’s Executive Leadership Team that crafted the $10.2B sale from Nestle to the EQT Group.
5 years as Galderma’s North American President & GM, scaling Aesthetics, Consumer, and Prescription businesses by 50%+ to $2.1B+ across Dysport®, Sculptra®, Restylane®, Cetaphil®, Differin®, Proactiv® and Epiduo®.
Attained the 1st FDA-approved RX-to-OTC acne switch in 30 years.
SVP and VP for Novartis across multiple verticals-Pharma, Oncology, Nutrition and Consumer.
M.D. Faculty of Medicine,Universidad Nacional Autónoma de México (UNAM), Mexico City.
Ph.D. (Experimental Medicine) Department of Surgery, Plastic and Re-constructive Surgery, UBC.
6 translational tissue-engineering programs (in-vivo bioreactor, liquid skins ubstitute, 3-D bladder/kidney tumor platforms.
10+ pre-clinical / animal studies advancing regenerative surgery toward clinic.
40+ Published peer-reviewed clinical and research papers (plastic surgery, wound healing, stem-cell therapy, 3-D bio-printing)
1 U.S. patent (+ licensed IP) for an implantable modular bio-reactor sold to the U.S. Army
8 Industry & academic collaborations in regenerative medicine.
25+ years in dermatology and aesthetics, he served as CMO of Suneva Medical (acquired by Tiger Bio, 2024) and VP of Medical Affairs for Merz North America, leading the launch of Radiesse.
8 FDA-related post-market / label-expansion programs (Radiesse®, Xeomin®, Belotero®, Instalift®, HD-PRP, etc.)
15 clinical programs in regenerative aesthetics, fillers and thread-lifts.
20+ Published Research Papers (PMMA collagen filler science, wound biology).
25 patents (3 direct-inventor; 22 co-inventor) on aromatic-aldehyde dermatologic therapeutics & ECM biology.
10 Affiliated Aesthetic / Pharma Companies (Merz, Suneva, Endo, Sinclair, Servier, Roche, Cytrellis, Camurus, Paradigm, Premier HC).
Financial executive with nearly 40 years in accounting and tax management.
Co-founded a Canadian biotech developing bio-pharmaceutical products. Deep expertise in small-cap markets, securities regulations, and corporate governance.
Managed audits for multiple go-public transactions, supporting capital raises and growth initiatives.
25 year entrepreneur and capital markets professional with experience leading a Canadian biotech from startup to IPO, raising $30M in 9 months.
Founder of Conexeu Sciences; led the acquisition of the Conexeu’s global core collagen/ECM IP on an outright basis. (no licensing fees or royalty obligations)
Raised and advised on more than $8M in Conexeu seed capital, coordinating early-stage financings and investor syndicates.
Assembled Conexeu’s world-class management and advisory team across regenerative medicine, aesthetics, wound care, and capital markets.
20+ years of experience in operational excellence, brand development, M&A integration, finance, and commercial growth. Experience includes roles across Fortune 500 and global healthcare organizations. Held multiple positions at Galderma spanning Marketing, Finance, Project Management, Launch Excellence, and Commercial Strategy.
Earlier career included leadership roles in audit, finance, integration, and operations across financial services and investment banking.
Recognized by Fort Worth CEO Magazine as a Top 20 Woman to Watch in Business.
25+ years in finance, transformation, and corporate development, supporting CEOs, boards, and private equity sponsors.
Transaction experience spans across M&A, licensing, carve-outs, IPO readiness, restructurings, and exits.
Founder of Allyght Advisory, serving private equity-backed and privately held companies including structuring strategic partnerships and advising executive teams on growth and transaction execution.
Former Vice President of Corporate Development and Head of Transactions at Galderma, with responsibility for acquisitions, divestitures, licensing agreements, and IPO readiness.
Chair of the Board with a track record of scaling ventures from startup to IPO, including a biotech that raised $30M in 9 months.
Guided numerous private companies to public listings, generating ~$100Min financing with expertise in IPOs and M&A.
Awarded Canada’s Top 40 Under 40 forleadership at a national start-up.
Active investor and advisor, focused on helping emerging companies transition from private to public markets and achieve successful exits.
Dr. Lorenc is board certified by theAmerican Board of Plastic Surgery, a member of the American Society of PlasticSurgeons, International Society of Aesthetic Plastic Surgery.
Advised J&Jon Evolence collagen filler acquisition ($159M)
10 FDA pivotal trials(supporting regulatory clearances)
25+clinical studies on dermal fillers, neurotoxins, lasers and surgical devices
100+Published Research Papers (peer reviewed aesthetic manuscripts)
39patents covering soft-tissue augmentation, surgical appliances, antimicrobial sutures, collagen formulation.
20+sponsor & industry affiliations—Allergan, Galderma, Merz Aesthetics, Chroma, Teoxane, Krystal Bio
CEO and Chief Investment Officer of 1.2 Capital, an alternative investment management firm.
ResearchGrants awarded from American PhilosophicalAssociation, National Endowment for the Humanities, and NationalEndowment for the Arts.
Lectured at Princeton,Columbia and McGill University
Work featured in multiple outlets including: The Guardian,BBC World, and Time Magazine
Dr.Aaron Farberg is a double board-certified dermatologist and fellowship-trained Mohs surgeon practicing in Texas. He is the ChiefMedical Officer and founder of Bare Dermatology.
14 FDA Phase 3/3b registration‑supporting dermatology trials
35+clinical programs across medical & procedural dermatology biologics.
100+peer‑reviewed publications spanning skin cancer diagnostics and device‑based care.
1patent — Device to Aid in ArterialMicrovascular Anastomosis (US2016/50037).
20+sponsor & industry affiliations (trial sponsors and advisory roles) — Sanofi, AbbVie, Janssen, Lilly/Dermira, UCB, Incyte, Regeneron, Apogee, Alumis, Takeda, Novartis, Merck,Roche, Clinuvel, Blueprint Medicines; plus advisory, Galderma, Sun Pharma, Castle Biosciences, SurgiVance.
Dr. Rineer is a Fellow of the American Academy of Emergency Medicine & a Fellow of the American College of Emergency Physicians. In addition, he is member of the American Medical Association and the Florida Medical Association.
U.S. Marine Corps Surgeon Forces Central including: Service in Afghanistan.
U.S. Navy/USMC parachutist.
An expert in wounds and trauma injuries.
Specialist for Implantology (DGI / NvOI), implant prosthetics& dental technology.
Co‑founder, Implant Competence Centrum (ICC‑M), Munich (2009)
Assistant Director, Centre for Implantology & Periodontology, Amstelveen, NL
DGI educator and leadership roles in Germany
Global KOL, Randelzhofer is invited worldwide to lecture/teach on implant aesthetics
Dr. Gorantla is tenured Professor of Surgery at Wake Forest University School of Medicine and the Wake Forest Institute for Regenerative Medicine.
His research interests include: cellular therapies, nano medicine, organ transplantations, re-constructive surgeries, regenerative medicine.
Key member of the team that performed first U.S. hand transplant team (1999, Sponsored by the Department of Defense).
Completed 8 transplants in 5 patients, including the nation’s first bilateral and full forearm transplants.
Dr. Anthony Papp is a royal College board‑certified plastic surgeon, 25+ years’ experience.
President, Canadian Burn Association
Medical Director, BC Professional Firefighters’ Burn Unit
World‑renowned expert in plastic surgery, burn care, wound healing & scar management
Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old. Richard McClintock, a Latin professor at Hampden-Sydney College in Virginia, looked up one of the more obscure Latin words, consectetur, from a Lorem Ipsum passage, and going through the cites of the word in classical literature, discovered the undoubtable source.Lorem Ipsum comes from sections 1.10.32 and 1.10.33 of "de Finibus Bonorum et Malorum" (The Extremes of Good and Evil) by Cicero, written in 45 BC. This book is a treatise on the theory of ethics, very popular during the Renaissance. The first line of Lorem Ipsum, "Lorem ipsum dolor sit amet..", comes from a line in section 1.10.32.The standard chunk of Lorem Ipsum used since the 1500s is reproduced below for those interested. Sections 1.10.32 and 1.10.33 from "de Finibus Bonorum et Malorum" by Cicero are also reproduced in their exact original form, accompanied by English versions from the 1914 translation by H. Rackham.
